首页|Community prevention and standardized clinical treatment jointly improve cancer outcome:Real-world evidence from an esophageal cancer patient cohort study

Community prevention and standardized clinical treatment jointly improve cancer outcome:Real-world evidence from an esophageal cancer patient cohort study

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Community prevention and standardized clinical treatment jointly improve cancer outcome:Real-world evidence from an esophageal cancer patient cohort study
Extensive efforts have been put into reducing the heavy burden of esophageal squamous cell carcinoma(ESCC)in China.However,the joint impact of prevention and treatment on the long-term overall survival(OS)of ESCC patients remains largely unknown.We consecutively recruited 13,255 ESCC patients from two Chinese centers:the Northern center,located in a high-risk area with abundant screening programs;and the Southern center,situated in a non-high-risk area with improved clinical practices.Inter-center comparison,longitudinal intra-center comparison,and a simulation analysis were conducted to investi-gate the influence of tumor downstaging and high-quality clinical treatment on OS.During a follow-up period of 12.52 years,the Northern center exhibited higher median survival than the Southern center(6.22 vs.3.15 years;HRadjusted=0.73,95％CI:0.69-0.77).Mediation analysis demonstrated that its OS advantage was largely(77.7％)attributed to earlier TNM stage(stage 0-Ⅱ:51.3％vs.24.6％).In temporal analyses,patient survival in the Southern center gradually improved(median survival during 2015-2018 vs.2009-2014:3.58 vs.2.93 years;HRadjusted=0.86,95％Cl:0.79-0.94),coinciding with the progress of treatment-related indices(completeness of TNM staging in discharge diagnosis[from 53.7％to 99.6％],adoption of minimally invasive esophagectomy[from 0.0％to 51.1％]and right thoracic esophagectomy[from 12.4％to 86.4％],etc.).Simulation analysis further demonstrated that integrating both downstaging and high-quality treatment would lead to the best survival.Tumor downstaging and high-quality clinical treatment have a joint impact on ESCC patient survival.Establishing a comprehensive strategy that inte-grates cancer prevention with optimal clinical treatment is crucial for alleviating the ESCC burden.

Esophageal squamous cell carcinomaTumor downstagingHigh-quality clinical treatmentSurvivalReal-world

Ji Ke、Fangfang Liu、Wei Yang、Ruiping Xu、Lei Chen、Wenlei Yang、Yu He、Zhen Liu、Bolin Hou、Liqun Zhang、Miaoping Lin、Lixin Zhang、Fan Zhang、Fen Cai、Huawen Xu、Mengfei Liu、Ying Liu、Yaqi Pan、Zhonghu He、Yang Ke

展开 >

Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Genetics,Peking University Cancer Hospital & Institute,Beijing 100142,China

Cancer Hospital of Shantou University Medical College,Shantou 515031,China

Anyang Cancer Hospital,Anyang 455000,China

Department of Non-communicable Disease Epidemiology,London School of Hygiene & Tropical Medicine,London WC1E 7HT,UK

Linkdoc AI Research(LAIR),Beijing 100080,China

State Key Laboratory of Molecular Oncology,Beijing Key Laboratory of Carcinogenesis and Translational Research,Department of Genetics,Peking University Cancer Hospital& Institute,Beijing 100142,China

展开 >

Esophageal squamous cell carcinoma Tumor downstaging High-quality clinical treatment Survival Real-world

2024

10.1016/j.scib.2024.11.005

科学通报(英文版)
中国科学院

科学通报(英文版)

CSTPCD
ISSN：1001-6538
年,卷(期)：2024.69(24)